Rapid Diagnostics Market Segment Expansion Driven by Infectious Disease Dominance
The Rapid Diagnostics Market Segment overview reveals that infectious disease testing remains the largest segment, accounting for nearly half of global revenues. This includes testing for flu, malaria, tuberculosis, HIV, and emerging pathogens. Glucose monitoring devices, pregnancy kits, and cardiac marker tests form the next major segments, with strong demand in home and clinical settings. By platform, lateral flow immunoassays dominate due to cost and ease of use, while molecular assays grow rapidly as accuracy becomes increasingly critical. End-user segmentation highlights hospitals, clinics, diagnostic laboratories, and home users as primary groups. OTC distribution channels are showing faster growth than traditional pharmacies, reflecting consumer preference for self-diagnosis and convenience. With each segment evolving uniquely, companies are diversifying product portfolios to maintain competitiveness across categories.